Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

摘要

BACKGROUNDBevacizumab (Bev) has gained acceptance as an active agent in the treatment of epithelial ovarian cancer (EOC). Data is lacking on survival outcomes in patients who are re-treated with Bev after achieving a complete response to a Bev-containing regimen (BCR). Our primary objective was to compare the progression free survival (PFS) and overall survival (OS) in patients who received Bev after Bev (BAB) versus those who were not re-treated with Bev (NOTBev) after initially experiencing a complete response (CR) to a BCR.